前列腺MRI深度学习模型通过PI-RADS指导的学习有效区分中危病例，在检测csPCa的AUC（0.73-0.88）显著优于放射科医生和临床模型 ...

本研究对比了PI-RADS v2.1与v2.0在多参数MRI（mpMRI）诊断临床显著前列腺癌（csPCa）中的性能。结果显示，v2.1通过优化移行带（TZ）病灶评估标准，显著提升了TZ区域csPCa的检出率（55.1% vs 39.3%），且多变量分析证实其优势（OR=1.34）。研究证实v2.1在标准化前列腺影像 ...

Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer. This is an ASCO Meeting Abstract from the 2020 Genitourinary Cancers Symposium. This abstract does not include a ...

Targeting PI-RADS 4 and 5 lesions for confirmatory biopsy improves detection of clinically significant cancer. The following article is part of conference coverage from the 2017 American Urological ...

Survival impact of initial local therapy selection for men under 60 with high risk prostate cancer. Prostate cancer (PCa) in 696 hypogonadal men with and without long-term testosterone therapy (TTh): ...

Upgrade and downgrade rates from targeted biopsy to radical prostatectomy were not significantly different between patients whose MRI examinations were clinically interpreted using PI-RADS Version ...

PI-RADS version 2.1 demonstrated improved detection of clinically significant prostate cancer in the transition zone. For detecting clinically significant prostate cancer (csPCa), prostate imaging ...